Drug Discovery World

JANUARY 16, 2023

BioGrad, a company offering medical and scientific support for education and research organisations, is to open the UK’s second largest biobank facility in Liverpool, as part of a £7.6m investment into a new headquarters at Wavertree Technology Park. . In collaboration with the University of Leicester, BioGrad biobank has already welcomed up to 261,000 samples from the largest long-Covid study in the UK.

Research 246

Research Hospitals Science Drugs 246

Drug Channels

JANUARY 17, 2023

Consolidation has brought together large, economically significant insurer/PBM/specialty pharmacy/provider organizations within U.S. drug channels. At least half of all U.S. healthcare spending flows through these seven familiar entities: Blue Cross Blue Shield, Centene, Cigna, CVS Health, Elevance Health, Humana, and United Health Group. In the brief video clip below, I review these businesses and offer some thoughts on their positioning for 2023.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Drugs 98

Antidote

JANUARY 17, 2023

Hemophilia is a disease in which the blood does not clot properly. It is rare and typically hereditary, often leading to spontaneous or excessive bleeding, especially following injuries or surgery, and internal bleeding can be a major risk factor. Below, we’re exploring a few hemophilia facts many people may not know.

International 98

International Disease 98

Drug Patent Watch

JANUARY 20, 2023

Annual Drug Patent Expirations for CARNEXIV Carnexiv is a drug marketed by Lundbeck Pharms Llc and is included in one NDA. It is available from one supplier. There are six… The post New patent for Lundbeck Pharms drug CARNEXIV appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Discovery World

JANUARY 17, 2023

Oregon State University College of Pharmacy scientists have shown that lipid nanoparticles and messenger RNA could treat blindness associated with a rare genetic condition. . Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible. . The study, led by OSU Associate Professor of Pharmaceutical Sciences Gaurav Sahay, Oregon State doctoral student Marco Herrera-Barrera, and Oregon Health &

Small Molecule 246

Small Molecule Pharmacy RNA Packaging 246

Drug Channels

JANUARY 20, 2023

Today’s blog post comes from Andrew Duncan, Vice President of Business Operations and Analytics at PHIL. Andrew discusses how manufacturers can use data-driven strategy to understand utilization, increase patient access and adherence, and optimize gross-to-net. Click here to learn more about PHIL’s access and commercialization solutions. Read on for Andrew’s insights.

Drugs 52

Drugs 52

Drug Patent Watch

JANUARY 19, 2023

Annual Drug Patent Expirations for AMELUZ Ameluz is a drug marketed by Biofrontera and is included in one NDA. It is available from one supplier. There is one patent protecting… The post New patent for Biofrontera drug AMELUZ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Discovery World

JANUARY 20, 2023

News round-up for 19-20 January by DDW Digital Content Editor Diana Spencer. Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good news from Alto Neuroscience, everImmune, Avacta and Abionyx, though unfortunately things are not looking so rosy for Janssen’s HIV vaccine candidate.

Clinical Trials 130

Clinical Trials Vaccine Drugs Trials 130

Crucial Data Solutions

JANUARY 19, 2023

Demystifying and providing a solution for EHR to EDC interoperability has been a mission for CDS for the past four years. In this blog post, we break down various interoperability challenges and how the architecture of your eClinical software can be a game-changer. The post Making Data Exchange Feel Easy – Simplifying the Data Journey from EHR to EDC appeared first on Crucial Data Solutions.

52

52

Predictive Oncology

JANUARY 19, 2023

Predictive Oncology CEO Raymond Vennare and Dr. Robert Murphy, an inventor of the engine behind our artificial intelligence (AI) platform and new member of our Scientific Advisory Board, were featured in an interview with Natalie Stoberman from Proactive. They discuss the impact that Predictive Oncology has in defining an entirely new category of oncology drug discovery.

Engineering 52

Engineering Drugs 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

BMG Labtech

JANUARY 18, 2023

G protein-coupled receptors (GPCRs) are highly sophisticated detection molecules that can respond to signals as diverse as a photon or a hormone. They are as old as the first multicellular organisms that appeared on the Earth around 600 million years ago. And if you need to take an FDA-approved drug, there’s around a one in three chance that it’s a drug that targets a GPCR.

FDA Approval 52

FDA Approval FDA Research Drugs 52

Drug Discovery World

JANUARY 20, 2023

This paid-for advertorial by Labforward appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 Organisation leaders are facing ever-increasing pressures to digitise and future-proof their laboratories. The journey, however, to connecting a laboratory’s data, devices and people can be convoluted, particularly without the careful selection of solutions and tools that best-fit each laboratory’s specific requirements.

Laboratories 130

Laboratories Research Drugs 130

Drug Patent Watch

JANUARY 18, 2023

Annual Drug Patent Expirations for GENOSYL Genosyl is a drug marketed by Vero Biotech and is included in one NDA. It is available from one supplier. There are twenty-two patents… The post New patent for Vero Biotech drug GENOSYL appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Molecule Blog

JANUARY 18, 2023

IP-NFTs are non fungible tokens that represent legally binding intellectual property (IP) currently being used within decentralized science ( DeSci ). Here, we outline their inner workings and how you could utilize their metadata schema, data layer and smart contract methods to create your own intellectual property representation on EVM based blockchains.

Licensing 52

Licensing Licensing Packaging Laboratories 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Reprocell

JANUARY 18, 2023

Today, clinical trials are conducted to aid our understanding of, and to assess new treatments for, medical conditions or disorders that affect the human population. The plethora of investigative research initiated following the emergence of the coronavirus, SARS-CoV-2, in 2019 and the resultant development, and worldwide roll out, of a life-saving vaccine is one example of our current global clinical trial landscape.

Clinical Trials 52

Clinical Trials Trials Vaccine Treatment 52

Drug Discovery World

JANUARY 20, 2023

This paid-for advertorial by Aurora Microplates appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 Aurora Microplates is focused on making the highest quality, highest performing microplates available. The company uses the best materials, the cleanest and most precise moulding operations and facilities to deliver high performance microplates in a timely fashion.

Science 130

Science Assay Development Production Drugs 130

Drug Patent Watch

JANUARY 18, 2023

Annual Drug Patent Expirations for OPZELURA Opzelura is a drug marketed by Incyte Corp and is included in one NDA. It is available from one supplier. There are eleven patents… The post New patent for Incyte Corp drug OPZELURA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Cytel

JANUARY 17, 2023

When it comes to rare diseases, a handful of major challenges to drug development arise. Bayesians strategies have become a viable option, however, in overcoming some of the major obstacles faced by clinical trial sponsors in these areas.

Disease 52

Disease Clinical Trials Drug Development Trials 52

Labcorp Drug Development

JANUARY 17, 2023

Approaches to systemic anticancer therapy have shifted in recent decades. The nonspecific cytotoxic agents that once dominated the oncotherapy space first gave way to more targeted agents in the 1980s and 1990s, after which advanced, novel immunotherapeutic strategies took center stage. The potential of such immunotherapies to address untreatable malignancies … The post 4 emerging trends to watch in immunotherapy clinical trials appeared first on Insights From Our Labs to Yours.

Clinical Trials 52

Clinical Trials Trials Therapies Clinical Development 52

Drug Discovery World

JANUARY 20, 2023

Collaborative working between the NHS and industry could reduce variations in uptake of innovative treatments across the UK, a joint report from NHS Confederation and ABPI argues. Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and showed that uptake of new treatments in these areas continues to be below the average of similar countries in Europe.

Drugs 130

Drugs Government Treatment Science 130

Drug Patent Watch

JANUARY 17, 2023

Annual Drug Patent Expirations for NOURIANZ Nourianz is a drug marketed by Kyowa Kirin and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent expiration for Kyowa Kirin drug NOURIANZ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Sygnature Discovery

JANUARY 17, 2023

Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications. Sygnature Discovery’s acquisition of SB Drug Discovery This transaction will offer a strategic advantage for both companies, to enable further expansion of the businesses and their capabilities, and forms

Compound Screening 52

Compound Screening Marketing Assay Development Drugs 52

Dark Matter Blog

JANUARY 16, 2023

We are moving rapidly toward escape velocity in our RNA expedition at Arrakis. We want to mark this progress with some updates and perspectives in the Dark Matter blog. In the months ahead, we are rolling out a series of posts called “Fearlessly Forward” to bring you up to speed on how we’ve moved forward in our expedition. (We’ve been called crazy more than a few times, but we think a better word for Arrakeens is fearless.

Small Molecule 52

Small Molecule RNA Drugs International 52

Drug Discovery World

JANUARY 20, 2023

This is an extraordinarily exciting time to be involved in precision medicine for cancer. This new whitepaper reviews some of the topics and trends in this emerging research area, including: 3D cultures: Spheroids and organoids Organoids in cancer research Tumour microenvironments Organ-on-a-chip and body-on-a-chip 3D bioprinting The post Trends in precision medicine: Cancer appeared first on Drug Discovery World (DDW).

Research 130

Research Drugs Drug Development 130

Drug Patent Watch

JANUARY 17, 2023

Annual Drug Patent Expirations for ORAVERSE Oraverse is a drug marketed by Septodont Holding and is included in one NDA. It is available from one supplier. There are three patents…. The post New patent for Septodont Holding drug ORAVERSE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

DrugBank

JANUARY 17, 2023

Most of us know that without high quality data we can be left making assumptions that result in flawed research, bad decisions, and worse health outcomes. But knowing that we need quality data isn’t enough if we also don’t know what quality looks like.   It can be tough to define quality in a succinct way because the metrics for success are so dependent on who is using the data and what they’re using it for.

Drugs 52

Drugs Production Research 52

New Drug Approvals

JANUARY 16, 2023

‘Top 10 Prominent & Great Personalities of the year 2022’ campaign by Fame Finders. Feeling great to be selected in the ‘Top 10 Prominent & Great Personalities of the year 2022’ campaign by Fame Finders. It is an online campaign to honour inspiring personalities and feature them in the upcoming edition of the top news sites, including – Deccan Chronicle/Asian Age/Deccan Herald, ANI, Zee5, Latestly, Lokmat Times, DailyHunt, Google News, JioNews, MSN and 70+ s

Organic Chemistry 52

Organic Chemistry Drugs 52

Drug Discovery World

JANUARY 20, 2023

Precision medicine uses information about an individual’s genes, proteins, and environment to prevent, diagnose, and treat diseases, including cancer. Differences in DNA, RNA, and protein can be identified in individual tissue samples, and even in individual cells. The massive data sets generated from this research have driven advances in data science and are used to inform additional studies and clinical practice.

RNA 130

RNA DNA Science Research 130

Drug Patent Watch

JANUARY 17, 2023

Annual Drug Patent Expirations for VRAYLAR Vraylar is a drug marketed by Allergan and is included in one NDA. It is available from two suppliers. There are four patents protecting…. The post New patent for Allergan drug VRAYLAR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advarra

JANUARY 17, 2023

A highly valuable tool for research staff, electronic consent (eConsent) can simplify the consenting process for both staff and participants. Used effectively, eConsent can increase consenting quality while reducing audit findings at sites. As the industry continues to shift from studies conducted exclusively in person to more convenient hybrid formats, eConsent can be very useful. .

Research 52

Research Trials Compliance 52

Eye on FDA

JANUARY 16, 2023

Through its Human Drugs Advisory Committee process FDA has a vast array of outside experts to consult on matters related to product approval as well as questions about policy or safety issues concerning approved products. The mechanism provides an open and transparent process whereby people can see and hear the deliberations and have input during open public comment as well as through a docket established for that purpose.

FDA 52

FDA FDA Approval Production Therapies 52

Drug Discovery World

JANUARY 19, 2023

By DDW Editor Reece Armstrong The looming threat of global warming, consequences of which can already be seen and felt across the planet, will impact us all. It seems that despite a constant barrage of warnings by scientists and experts, alongside visible effects such as wildfires, droughts, and blistering heatwaves, we still aren’t doing enough to tackle it.

Pharmaceuticals 130

Pharmaceuticals Pharmaceutical Companies Clinical Trials Government 130

Drug Patent Watch

JANUARY 17, 2023

Annual Drug Patent Expirations for AKYNZEO Akynzeo is a drug marketed by Helsinn Hlthcare and is included in two NDAs. It is available from one supplier. There are nineteen patents…. The post New patent for Helsinn Hlthcare drug AKYNZEO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Conversations in Drug Development Trends

JANUARY 17, 2023

Ryan Gladden, our colleague and Black, Indigenous, People of Color (BIPOC) Employee Resource Group (ERG) member, shared his reflections on MLK Day. The post Reflections on Martin Luther King Jr. Day 2023 appeared first on Worldwide Clinical Trials.

Clinical Trials 52

Clinical Trials Trials 52